Previous 10 | Next 10 |
Gainers: Synthetic Biologics (SYN) +149%, Check-Cap (CHEK) +59%, Jaguar Health (JAGX) +50%, Cyclo Therapeutics CYTH +36%, Zomedica (ZOM) +42%.Losers: Bionano Genomics BNGO -29%, Mersana Therapeutics (MRSN) -23%, Millendo Therapeutics...
Following successful FDA meeting, the Company plans to initiate UPLIFT, a single-arm registrational strategy to evaluate XMT-1536 in platinum-resistant ovarian cancer, in Q1 2021 Data from the ovarian cancer expansion cohort of the XMT-1536 Phase 1 study continued to show co...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Final 2020 year-end report card for the MDA Breakout stocks now beating the S&P 500 for the fourth year in a row with +73.4% returns through 52 weeks. 2020 data shows that following the Momentum Gauges to avoid 20 weeks of negative signals delivered +94.7% returns in the remaining...
CAMBRIDGE, Mass., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced...
The 2020 year end report card for the MDA Breakout stocks now beating the S&P 500 for the fourth year in a row with +50.3% returns through 50 weeks. 2020 data shows that following the Momentum Gauges® to avoid 20 weeks of negative signals delivered +71.7% returns in the remai...
CAMBRIDGE, Mass., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announce...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Immunosynthen ADCs activate the STING pathway in both tumor-resident immune cells and in the tumor cells , resulting in robust anti-tumor activity and offer ing a differentiated approach from other innate immune activators CAMBRIDGE, Mass., Nov. 11, 2...
Mersana Therapeutics, Inc. (MRSN) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Sarah Carmody – Executive Director, Investor Relations and Corporate Communications Anna Protopapas – President and Chief Executive Officer Brian DeSchuytner ...
News, Short Squeeze, Breakout and More Instantly...
Mersana Therapeutics Inc. Company Name:
MRSN Stock Symbol:
NASDAQ Market:
Mersana Therapeutics Inc. Website:
Maximum tolerated dose not yet established in Phase 1 clinical trial of XMT-1660; enrollment in dose escalation and backfill cohorts continuing in parallel; expect to announce initial clinical data and initiate expansion in the second half of 2024 Patient recruitment ongoing in Phase 1 cl...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that ...
2024-03-18 08:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...